NCT02840565View on ClinicalTrials.gov

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
HypertensionChronic Heart Failure
Interventions
DRUG

BIA 5-453

Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

DRUG

Placebo

The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 | Biotech Hunter | Biotech Hunter